Indivior plc announced results from a randomized, double-blind clinical trial published in JAMA Network Open evaluating extended-release buprenorphine (SUBLOCADE®) for moderate-to-severe opioid use disorder. The study found that both 100-mg and 300-mg monthly maintenance doses of SUBLOCADE rapidly reduced opioid use and improved abstinence, with no new safety signals identified. Post-hoc analyses indicated the 300-mg dose performed significantly better than the 100-mg dose in participants reporting high-frequency fentanyl use. Injection-site reactions were more common at the higher dose but were mild to moderate and did not lead to discontinuation. The results have already been presented.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indivior plc published the original content used to generate this news brief via PR Newswire (Ref. ID: PH49913) on December 17, 2025, and is solely responsible for the information contained therein.